Multiple Sclerosis, Secondary Progressive: Clinical Trials

7 trials for Multiple Sclerosis, Secondary Progressive, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 recruiting, 1 unknown. 7 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 17Completed 5, Recruiting 1, Unknown 1
Phase 24Completed 3, Unknown 1

Follow Multiple Sclerosis, Secondary Progressive: new trials by email Literature Review of Multiple Sclerosis, Secondary Progressive trials Research Report on Multiple Sclerosis, Secondary Progressive

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
PIPE-791 - Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
Phase 1CompletedContineum Therapeutics162024-12-092025-08-06
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen - Multiple Sclerosis, Multiple Sclerosis, Primary Progressive
Phase 1RecruitingStanford University122024-04-102026-02-27
Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis
Extracorporeal Photopheresis, MS standard of care - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Phase 1 / Phase 2CompletedAbu Dhabi Stem Cells Center152022-03-262026-05-07
Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis
Insulin, Placebo (Sterile diluent) - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Phase 1 / Phase 2CompletedJohns Hopkins University1052017-12-012023-03-10
Open-label Study of Liothyronine in MS
liothyronine - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Phase 1CompletedJohns Hopkins University202015-07-012018-02-12
Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
Andrographolides, placebo - Primary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive
Phase 1 / Phase 2UnknownInnobioscience SpA682014-09-012014-10-27
Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis
Tovaxin Autologous T Cell Vaccine - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Phase 1 / Phase 2CompletedOpexa Therapeutics, Inc.162002-07-012017-01-11

Narrower conditions

Multiple Sclerosis, Chronic Progressive (7)  ·  Multiple Sclerosis, Relapsing-Remitting (4)  ·  Multiple Sclerosis (3)  ·  Autoimmune Diseases (2)  ·  Autoimmune Diseases of the Nervous System (1)  ·  Demyelinating Autoimmune Diseases, CNS (1)  ·  Demyelinating Diseases (1)  ·  Idiopathic Pulmonary Fibrosis (1)  ·  Immune System Diseases (1)  ·  Nervous System Diseases (1)  ·  Neuroinflammatory Diseases (1)  ·  Pathologic Processes (1)  ·  Sclerosis (1)

Broader conditions

Chronic Disease (7)  ·  Disease Attributes (7)  ·  Pathological Conditions, Signs and Symptoms (7)  ·  Autoimmune Diseases of the Nervous System (6)  ·  Demyelinating Autoimmune Diseases, CNS (6)  ·  Demyelinating Diseases (6)  ·  Immune System Diseases (6)  ·  Nervous System Diseases (6)  ·  Pathologic Processes (6)  ·  Autoimmune Diseases (5)  ·  Multiple Sclerosis (4)  ·  Brain Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Inflammation (1)  ·  Leukoencephalopathies (1)

Interventions

Bendamustine Hydrochloride (1)  ·  Insulin (1)  ·  Photochemotherapy (1)  ·  Photopheresis (1)  ·  Triiodothyronine (1)  ·  andrographolide (1)  ·  neoandrographolide (1)

Sponsors

Johns Hopkins University (2)  ·  Abu Dhabi Stem Cells Center (1)  ·  Contineum Therapeutics (1)  ·  Innobioscience SpA (1)  ·  Opexa Therapeutics, Inc. (1)  ·  Stanford University (1)

Countries

United States (4)  ·  Chile (1)  ·  United Arab Emirates (1)  ·  United Kingdom (1)

Top investigators

Scott Newsome, DO (2)  ·  Ellen Mowry, MD, MCR (1)  ·  Jaye Thompson, PhD (1)  ·  Jeffrey Dunn, MD (1)  ·  Juan L Hancke, DVM, PhD (1)  ·  Stephen Huhn, MD (1)  ·  Yendry Ventura Carmenate, M.D. (1)

Results publications

PMID 32380977